Hodgkin's Lymphoma

Oncology
4
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

ADC
150%
Monoclonal Antibody
150%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

TG Therapeutics
TG TherapeuticsNEW YORK, NY
2 programs
1
1
PembrolizumabPhase 2Monoclonal Antibody1 trial
TGR-1202 + brentuximab vedotinPhase 1ADC1 trial
Active Trials
NCT02164006Completed16Est. May 2016
NCT03776864TerminatedEst. Sep 2021
Teva
TevaIsrael - Petach Tikva
1 program
1
Obatoclax mesylatePhase 21 trial
Active Trials
NCT00359892Completed13Est. Nov 2008
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
AMG 655Phase 11 trial
Active Trials
NCT00791011Completed33Est. Aug 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TG TherapeuticsPembrolizumab
TevaObatoclax mesylate
TG TherapeuticsTGR-1202 + brentuximab vedotin
AmgenAMG 655

Clinical Trials (4)

Total enrollment: 62 patients across 4 trials

NCT03776864TG TherapeuticsPembrolizumab

Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Start: Sep 2019Est. completion: Sep 2021
Phase 2Terminated
NCT00359892TevaObatoclax mesylate

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma

Start: Jul 2006Est. completion: Nov 200813 patients
Phase 2Completed
NCT02164006TG TherapeuticsTGR-1202 + brentuximab vedotin

Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

Start: Jun 2014Est. completion: May 201616 patients
Phase 1Completed
NCT00791011AmgenAMG 655

Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat

Start: Feb 2008Est. completion: Aug 201133 patients
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)